A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT ID: NCT06632600
Last Updated: 2025-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
130 participants
INTERVENTIONAL
2025-04-28
2027-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
NCT04024163
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
NCT05957978
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
NCT05593666
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
NCT02369978
Syndecan-4 as a Biomarker in Patients With Chagas Disease
NCT01842867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
For the LXE and placebo arms:
Participants, investigator, staff, and persons performing the assessments will remain blinded to the identity of the treatment from the time of randomization until final (12 month) database lock for blinded arms. The sponsor clinical trial team (CTT) will be blinded until the primary endpoint analysis (when all participants complete 6 month visit) and may become unblinded as needed at any other interim analysis.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LXE408 28 days
LXE408 administered by oral route
LXE408
LXE408 administered by oral route
LXE408 14 days and Placebo 14 days
LXE408 administered by oral route, followed by Placebo administered by oral route
LXE408
LXE408 administered by oral route
Placebo
Placebo administered by oral route
Placebo 28 days
Placebo administered by oral route
Placebo
Placebo administered by oral route
Benznidazole 60 days
Benznidazole administered by oral route
Benznidazole
Benznidazole administered by oral route (administered as standard of care)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LXE408
LXE408 administered by oral route
Placebo
Placebo administered by oral route
Benznidazole
Benznidazole administered by oral route (administered as standard of care)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of T. cruzi infection
* History that participant has been determined to be in chronic phase of CD
* Written informed consent must be obtained before any assessment is performed, and participants should express understanding of the consent form and the study
* Participants must be considered by the investigator eligible for and able to comply with local prescribing information for benznidazole
* Ability and willingness to communicate well with the investigator/study site and comply with requirements of the study
Exclusion Criteria
* History of CD treatment with benznidazole or nifurtimox at any time in the past
* History of and/or current (at screening) symptoms or signs (physical examination findings) of moderate or severe CD-related gastrointestinal disease
* Participants who weigh \< 50 kg or \>90kg at screening
* At sites conducting the MRI assessments, participants may participate in the overall study, but will be excluded from the MRI assessment if they have contraindications to MRI imaging
* Any clinically significant disease during screening that, in the opinion of the investigator, would put the safety of the participant at risk through participating, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study, or would compromise participant compliance or preclude completion of the study
* Documented history or current findings at screening of clinically significant cardiovascular conditions such as, but not limited to: unstable ischemic heart disease; NYHA Class III/IV heart failure (due to Chagas disease or other conditions); arrhythmias
* Known or suspected ongoing, chronic or recurrent viral, bacterial or fungal infectious diseases including but not limited to: Tuberculosis, leishmaniasis, severe malaria, atypical mycobacterial infection, listeriosis, aspergillosis, or endemic mycoses, and/or documented positivity for human immunodeficiency virus (HIV) infection
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years prior to screening (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)
* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant during the study period
* Pancreatic injury or pancreatitis: If any single parameter of amylase or lipase exceeds 1.5x ULN at screening Participants with known recurrent pancreatitis (more than 1 episode in lifetime, from any cause) are excluded
* Liver disease or liver injury as indicated by abnormal liver function tests (LFTs):
Any single parameter of ALT, AST, GGT, alkaline phosphatase must not exceed 1.5x ULN at screening Serum bilirubin must not exceed the ULN at screening elevated serum bilirubin is not excluded if there is a documented history of Gilbert's Syndrome
• History of renal disease as indicated by creatinine level above 1.5x ULN or microalbuminuria or hematuria at screening; Evidence of urinary obstruction, or difficulty in voiding at screening; evidence of congenital renal abnormalities with known effect on renal function; calculated eGFR \<60 mL/min (\<0.835 mL/s) using the CKD-EPI formula for adults
* Participants with screening hematology parameters outside of the thresholds
* Current use of medications prohibited by the protocol at screening and/or baseline visits, or expected use of any prohibited medication during the study treatment period
* Use of other investigational drugs at the time of study drug dosing
* History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study or to benznidazole
* History of drug abuse or unhealthy alcohol use within the 12 months prior to dosing
* Pregnant or nursing (lactating/breast-feeding) women
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping of investigational drug and benznidazole
* Participants who, in the opinion of the investigator, will not be able to comply with study procedures or visits, adhere to dosing schedule, or other otherwise be in compliance with study requirements
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Olive View UCLA Educ and Res Ins
Sylmar, California, United States
University of Florida Shands
Gainesville, Florida, United States
Boston Medical Center
Boston, Massachusetts, United States
Baylor College of Medicine
Houston, Texas, United States
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Corrientes, , Argentina
Novartis Investigative Site
Córdoba, , Argentina
Novartis Investigative Site
Formosa, , Argentina
Novartis Investigative Site
Montes Claros, Minas Gerais, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
São Caetano do Sul, São Paulo, Brazil
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Yopal, Casanare Department, Colombia
Novartis Investigative Site
Bogotá, , Colombia
Novartis Investigative Site
Bogotá, , Colombia
Novartis Investigative Site
Floridablanca, , Colombia
Novartis Investigative Site
San Gil, , Colombia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Novartis Pharmaceuticals
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLXE408B12201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.